In this issue:
The anticoagulant agent osocimab in haemodialysis patients
Uptake of SGLT2 inhibitors in Australian patients with CKD
Under-representation of patients with CKD in trials of cardiovascular drugs
Real-world dapagliflozin utilisation in patients with CKD
Stereotactic ablative body radiotherapy for primary kidney cancer
Novel candidate filtration markers for GFR estimation
Warfarin and rivaroxaban vs apixaban in patients with advanced CKD and atrial fibrillation
Ofatumumab in rituximab-resistant or rituximab-intolerant patients with primary membranous nephropathy
Heterogeneous treatment effects of intensive glycaemic control in type 2 diabetics
Prognostic biomarkers in kidney transplantation
Please login below to download this issue (PDF)